Premium
O5‐05‐01: Abeta oligomers as a pharmacodynamic biomarker of secretase therapy in Alzheimer's disease?
Author(s) -
Kalinina Juliya,
Michener Maria S.,
Smith Brad E.,
Parker Eric,
Stone Julie A.,
Kennedy Matthew,
Winrow Christopher J.,
Savage Mary J.
Publication year - 2015
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2015.07.469
Subject(s) - biomarker , pharmacodynamics , oligomer , pharmacology , dementia with lewy bodies , pharmacokinetics , chemistry , gamma secretase , alzheimer's disease , medicine , cancer research , disease , dementia , biochemistry , organic chemistry
group was found (Mean: 3.52 (95% confidence interval [CI], (1.29 to 5.75), p1⁄40.002). Further, in a per protocol analysis (defined as attendance >80% and exercise intensity >70% of maximal heart rate) we found a significant effect on the primary outcome in favor of the intervention group (SDMT: Mean: 4.18; (95% CI, -7.91 to -0.45); p1⁄40.03). For patients who exercised with the intended predefined intensity above 70 % of maximal heart rate, a positive correlation was found between attendance and improvement in SDMT (spearman r1⁄40.28; p1⁄40.01), suggesting a dose-response relationship between moderate to high intensity exercise and cognition. Conclusions: Although the study was negative on the primary outcome, exercise appears to reduce neuropsychiatric symptoms in patients with mild Alzheimer’s disease, with additional benefits of preserved cognition in a subgroup of patients with high attendance and intensity. Funded by The Danish Council for Strategic Research (j. no.: 10-092814); ClinicalTrials.gov number, NCT 01681602.